Opinion|Videos|December 9, 2024
NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Early and aggressive treatment strategies are crucial in reducing NMOSD relapse and hospitalization rates.
- Personalized treatment plans should incorporate new therapeutic agents and monitoring protocols for optimal outcomes.
A panelist discusses how neurologists can adapt their NMOSD management strategies based on recent findings about relapse and hospitalization rates, sharing practical advice and clinical experience for optimizing patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your clinical practice, how have you adapted your approach to NMOSD management in light of these recent findings on relapse and hospitalization rates?
- What advice do you have for other neurologists in managing patients with NMOSD and reducing relapse/hospitalization rates?
Advertisement
Related to this article
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Here's some of what is coming soon to NeurologyLive® this week.
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
2
Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show
3
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
4
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
5